Last reviewed · How we verify
Allogeneic T cell progenitors, cultured ex-vivo — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Allogeneic T cell progenitors, cultured ex-vivo (Allogeneic T cell progenitors, cultured ex-vivo) — Smart Immune SAS.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allogeneic T cell progenitors, cultured ex-vivo TARGET | Allogeneic T cell progenitors, cultured ex-vivo | Smart Immune SAS | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allogeneic T cell progenitors, cultured ex-vivo CI watch — RSS
- Allogeneic T cell progenitors, cultured ex-vivo CI watch — Atom
- Allogeneic T cell progenitors, cultured ex-vivo CI watch — JSON
- Allogeneic T cell progenitors, cultured ex-vivo alone — RSS
Cite this brief
Drug Landscape (2026). Allogeneic T cell progenitors, cultured ex-vivo — Competitive Intelligence Brief. https://druglandscape.com/ci/allogeneic-t-cell-progenitors-cultured-ex-vivo. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab